## James B Yu, Mhs

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3889179/publications.pdf

Version: 2024-02-01

23567 31849 13,058 364 58 101 citations h-index g-index papers 369 369 369 15747 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Geographic Access to Radiation Therapy Facilities in the United States. International Journal of Radiation Oncology Biology Physics, 2022, 112, 600-610.	0.8	18
2	Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma. Cancer Letters, 2022, 526, 346-351.	7.2	10
3	Hospital Frailty Risk Score and healthcare resource utilization after surgery for metastatic spinal column tumors. Journal of Neurosurgery: Spine, 2022, 37, 241-251.	1.7	10
4	Health Economics Research in Cancer Treatment: Current Challenges and Future Directions. Journal of the National Cancer Institute Monographs, 2022, 2022, 51-56.	2.1	6
5	Practice Patterns Related to Mitigation of Neurocognitive Decline in Patients Receiving Whole-Brain Radiation Therapy. Advances in Radiation Oncology, 2022, 7, 100949.	1.2	1
6	Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice, 2022, 9, 140-149.	0.5	0
7	Impact of Frailty on Morbidity and Mortality in Adult Patients Undergoing Surgical Evacuation of Acute Traumatic Subdural Hematoma. World Neurosurgery, 2022, 162, e251-e263.	1.3	2
8	A reply to "Randomized controlled clinical trial is needed for toxicity of IMRT VS 3D-CRT in PORT for LA-NSCLC― Lung Cancer, 2022, 168, 84-85.	2.0	0
9	PRO's Top 20 Downloads of 2021. Practical Radiation Oncology, 2022, 12, 176-178.	2.1	0
10	An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. Ca-A Cancer Journal for Clinicians, 2022, 72, 454-489.	329.8	13
11	A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer Journal of Clinical Oncology, 2022, 40, TPS5115-TPS5115.	1.6	0
12	A Special Series on Radiopharmaceutical Therapy. Practical Radiation Oncology, 2022, 12, 283-284.	2.1	0
13	Evaluation of social connectedness, loneliness, and anxiety among cancer survivors during the 2020-2021 winter surge of COVID-19 pandemic Journal of Clinical Oncology, 2022, 40, 12061-12061.	1.6	0
14	National trends in the management of patients with positive surgical margins at radical prostatectomy. World Journal of Urology, 2021, 39, 1141-1151.	2.2	0
15	Temporal Trends in Opioid Prescribing Patterns Among Oncologists in the Medicare Population. Journal of the National Cancer Institute, 2021, 113, 274-281.	6.3	25
16	Responses to the 2018 and 2019 "One Big Discovery―Question: ASTRO Membership's Opinions on the Most Important Research Question Facing Radiation Oncology…Where Are We Headed?. International Journal of Radiation Oncology Biology Physics, 2021, 109, 38-40.	0.8	4
17	Physician trajectories of abandoning longâ€course breast radiotherapy and their cost impact. Health Services Research, 2021, 56, 497-506.	2.0	1
18	Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. European Urology Oncology, 2021, 4, 327-330.	5.4	3

#	Article	IF	CITATIONS
19	Did quality of life for older cancer survivors improve with the turn of the century in the United States?. Journal of Geriatric Oncology, 2021, 12, 102-105.	1.0	1
20	Cost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer. JAMA Network Open, 2021, 4, e2033787.	5.9	5
21	Association between percentage of positive biopsy cores and risk of pelvic lymph node involvement in prostate cancer Journal of Clinical Oncology, 2021, 39, 205-205.	1.6	0
22	The Survival Advantage of Lobectomy over Wedge Resection Lessens as Health-Related Life Expectancy Decreases. JTO Clinical and Research Reports, 2021, 2, 100143.	1.1	1
23	Prevalence of Missing Data in the National Cancer Database and Association With Overall Survival. JAMA Network Open, 2021, 4, e211793.	5.9	66
24	Systematic review and meta-analysis of radiation therapy for high-risk non-muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 786.e1-786.e8.	1.6	5
25	Adoption of consolidative durvalumab among patients with locally advanced non-small cell lung cancer Journal of Clinical Oncology, 2021, 39, e20550-e20550.	1.6	0
26	Drivers of Medicare Spending: A 15-Year Review of Radiation Oncology Charges Allowed by the Medicare Physician/Supplier Fee-for-Service Program Compared With Other Specialties. International Journal of Radiation Oncology Biology Physics, 2021, 110, 322-327.	0.8	7
27	Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 495-501.	1.3	11
28	Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ. Journal of Clinical Oncology, 2021, 39, 2386-2396.	1.6	8
29	Practical Radiation Oncology's Top 20 Downloads of 2020. Practical Radiation Oncology, 2021, 11, 233-235.	2.1	0
30	Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis. Journal of Neuro-Oncology, 2021, 154, 197-203.	2.9	10
31	Social Connectedness Among Medicare Beneficiaries Following the Onset of the COVID-19 Pandemic. JAMA Internal Medicine, 2021, 181, 1245.	5.1	7
32	Post-operative radiation therapy for non-small cell lung cancer: A comparison of radiation therapy techniques. Lung Cancer, 2021, 161, 171-179.	2.0	2
33	Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients. Prostate Cancer and Prostatic Diseases, 2021, 24, 414-422.	3.9	9
34	National Quality Measure Compliance for Palliative Bone Radiation Among Patients With Metastatic Nonâ€"Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, , 1-6.	4.9	2
35	Impact of tissue heterogeneity correction on Gamma Knife stereotactic radiosurgery of acoustic neuromas. Journal of Radiosurgery and SBRT, 2021, 7, 207-212.	0.2	0
36	Emergency Department Visits for Radiation Cystitis Among Patients with a Prostate Cancer History. BJU International, 2021, , .	2.5	1

#	Article	IF	Citations
37	Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non–small cell lung cancer with brain metastases. Journal of Neurosurgery, 2020, 132, 512-517.	1.6	62
38	Perceptions of Prostate MRI and Fusion Biopsy of Radiation Oncologists and Urologists for Patients Diagnosed with Prostate Cancer: Results from a National Survey. European Urology Focus, 2020, 6, 273-279.	3.1	8
39	Early Impact of the Affordable Care Act and Medicaid Expansion on Racial and Socioeconomic Disparities in Cancer Care. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 163-167.	1.3	19
40	Proton-Based Chemoradiotherapy—What Level of Evidence Is Necessary to Justify Its Widespread Use?. JAMA Oncology, 2020, 6, 246.	7.1	1
41	The Association between the Affordable Care Act and Insurance Status, Stage and Treatment in Patients with Testicular Cancer. Urology Practice, 2020, 7, 252-258.	0.5	4
42	Multi-Institutional Validation of Deep Learning for Pretreatment Identification of Extranodal Extension in Head and Neck Squamous Cell Carcinoma. Journal of Clinical Oncology, 2020, 38, 1304-1311.	1.6	95
43	Emergency Department Visits for Opioid Overdoses Among Patients With Cancer. Journal of the National Cancer Institute, 2020, 112, 938-943.	6.3	29
44	Income disparities in needle biopsy patients prior to breast cancer surgery across physician peer groups. Breast Cancer, 2020, 27, 381-388.	2.9	1
45	Peer Influence on Physician Use of Shorter Course External Beam Radiation Therapy for Patients with Breast Cancer. Practical Radiation Oncology, 2020, 10, 75-83.	2.1	2
46	Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Advances in Radiation Oncology, 2020, 5, 26-32.	1.2	19
47	Radiation Dose to the Rectum With Definitive Radiation Therapy and Hydrogel Spacer Versus Postprostatectomy Radiation Therapy. Advances in Radiation Oncology, 2020, 5, 1225-1231.	1.2	0
48	Nationwide Patterns of Pathologic Fractures Among Patients Hospitalized With Bone Metastases. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 720-726.	1.3	8
49	National Patterns in Prescription Opioid Use and Misuse Among Cancer Survivors in the United States. JAMA Network Open, 2020, 3, e2013605.	5.9	47
50	Trends in Use and Comparison of Stereotactic Body Radiation Therapy, Brachytherapy, and Dose-Escalated External Beam Radiation Therapy for the Management of Localized, Intermediate-Risk Prostate Cancer. JAMA Network Open, 2020, 3, e2017144.	5.9	6
51	Nationwide patterns of hemorrhagic stroke among patients hospitalized with brain metastases: influence of primary cancer diagnosis and anticoagulation. Scientific Reports, 2020, 10, 10084.	3.3	4
52	Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases. JAMA Oncology, 2020, 6, 1028.	7.1	122
53	Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncology, The, 2020, 21, 655-663.	10.7	335
54	Resident attitudes and benefits of mock oral board examinations in radiation oncology. BMC Medical Education, 2020, 20, 203.	2.4	3

#	Article	IF	Citations
55	A general-purpose Monte Carlo particle transport code based on inverse transform sampling for radiotherapy dose calculation. Scientific Reports, 2020, 10, 9808.	3.3	12
56	Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today. International Journal of Radiation Oncology Biology Physics, 2020, 107, 334-343.	0.8	81
57	Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials. Radiotherapy and Oncology, 2020, 148, 235-242.	0.6	33
58	Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiotherapy and Oncology, 2020, 148, 157-166.	0.6	352
59	Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Advances in Radiation Oncology, 2020, 5, 659-665.	1.2	149
60	Geographic-Level Association of Contemporary Changes in Localized and Metastatic Prostate Cancer Incidence in the Era of Decreasing PSA Screening. Cancer Control, 2020, 27, 107327482090226.	1.8	3
61	Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer Journal of Clinical Oncology, 2020, 38, e19308-e19308.	1.6	0
62	RTOG 3506 (STEEL): A study of salvage radiotherapy with or without enzalutamide in recurrent prostate cancer following surgery Journal of Clinical Oncology, 2020, 38, TPS5601-TPS5601.	1.6	3
63	Temporal trends in opioid prescribing patterns among oncologists in the Medicare population Journal of Clinical Oncology, 2020, 38, 12022-12022.	1.6	1
64	Use of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer receiving immunotherapy Journal of Clinical Oncology, 2020, 38, e19309-e19309.	1.6	2
65	Emergency Department Visits for Firearm-Related Injuries among Youth in the United States, 2006–2015. Journal of Law, Medicine and Ethics, 2020, 48, 67-73.	0.9	0
66	Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era Journal of Clinical Oncology, 2020, 38, 748-748.	1.6	0
67	Multi-institutional retrospective review of stereotactic radiosurgery for brain metastasis in patients with small cell lung cancer without prior brain-directed radiotherapy. Journal of Radiosurgery and SBRT, 2020, 7, 19-27.	0.2	0
68	NIMG-03. DEEP LEARNING SURVIVAL ANALYSIS FOR MULTIPLE BRAIN METASTASES. Neuro-Oncology, 2020, 22, ii147-ii147.	1.2	0
69	BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction With Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study. Neurosurgery, 2019, 84, 868-880.	1.1	32
70	Association Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate Cancer. Urology, 2019, 124, 98-106.	1.0	9
71	Probing peripheral neural pathways in electrically stimulation induced sensation., 2019,,.		1
72	Estimating survival in patients with gastrointestinal cancers and brain metastases: An update of the graded prognostic assessment for gastrointestinal cancers (GI-GPA). Clinical and Translational Radiation Oncology, 2019, 18, 39-45.	1.7	26

#	Article	IF	Citations
73	Peer support: A needs assessment for social support from trained peers in response to stress among medical physicists. Journal of Applied Clinical Medical Physics, 2019, 20, 157-162.	1.9	8
74	Conservative management of lowâ€risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. Cancer, 2019, 125, 3338-3346.	4.1	15
75	Frequent Use of Local Therapy Underscores Need for Multidisciplinary Care in the Management of Patients With Melanoma Brain Metastases Treated With PD-1 Inhibitors. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1113-1118.	0.8	14
76	Minimum Data Elements for Radiation Oncology: An American Society for Radiation Oncology Consensus Paper. Practical Radiation Oncology, 2019, 9, 395-401.	2.1	20
77	Association between Long-Term Second Malignancy Risk and Radiation: A Comprehensive Analysis of the Entire Surveillance, Epidemiology, and End Results Database (1973-2014). Advances in Radiation Oncology, 2019, 4, 738-747.	1.2	6
78	Is Proton Therapy a "Pro―for Breast Cancer? A Comparison of Proton vs. Non-proton Radiotherapy Using the National Cancer Database. Frontiers in Oncology, 2019, 8, 678.	2.8	19
79	Methodology Flaws and Implications of a Complementary Medicine Studyâ€"In Reply. JAMA Oncology, 2019, 5, 433.	7.1	1
80	Analysis of the 2017 American Society for Radiation Oncology (ASTRO) Research Portfolio. International Journal of Radiation Oncology Biology Physics, 2019, 103, 297-304.	0.8	5
81	Defining an Intermediate-risk Group for Low-grade Glioma: A National Cancer Database Analysis. Anticancer Research, 2019, 39, 2911-2918.	1.1	8
82	Radiation Therapy for Renal Cell Carcinoma. Kidney Cancer, 2019, 3, 1-6.	0.4	2
83	A National Survey of Radiation Oncologists and Urologists on Perceived Attitudes and Recommendations of Active Surveillance for Low-Risk Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, e472-e481.	1.9	5
84	The case for radiotherapy in a Value based environment. Reports of Practical Oncology and Radiotherapy, 2019, 24, 200-203.	0.6	3
85	Differences in patterns of care and outcomes between grade II and grade III molecularly defined 1p19q co-deleted gliomas. Clinical and Translational Radiation Oncology, 2019, 15, 46-52.	1.7	9
86	AUTHOR REPLY. Urology, 2019, 124, 106.	1.0	0
87	Results of a pilot/phase II study of gamma knife radiosurgery for brain metastases and implications for future prospective clinical trials. Journal of Radiation Oncology, 2019, 8, 39-46.	0.7	0
88	Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma. Radiotherapy and Oncology, 2019, 134, 44-49.	0.6	12
89	Treatment-Related Complications of Systemic Therapy and Radiotherapy. JAMA Oncology, 2019, 5, 1028.	7.1	73
90	Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. Journal of Clinical Oncology, 2019, 37, 52-60.	1.6	218

#	Article	IF	Citations
91	Moderate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 619-627.	1.6	8
92	The ASTRO Research Portfolio: Where Do We Go From Here?. International Journal of Radiation Oncology Biology Physics, 2019, 103, 308-309.	0.8	1
93	Survival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress?. Translational Research, 2019, 208, 63-72.	5.0	13
94	Recommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. European Urology Oncology, 2019, 2, 189-195.	5.4	10
95	Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers. Obstetrical and Gynecological Survey, 2019, 74, 217-219.	0.4	2
96	Persistent Use of Extended Fractionation Palliative Radiotherapy for Medicare Beneficiaries With Metastatic Breast Cancer, 2011 to 2014. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 493-499.	1.3	8
97	Breast cancer patients with brain metastasis undergoing GKRS. Breast Cancer, 2019, 26, 147-153.	2.9	5
98	Perceptions of Barriers Towards Active Surveillance for Low-Risk Prostate Cancer: Results From a National Survey of Radiation Oncologists and Urologists. Annals of Surgical Oncology, 2019, 26, 660-668.	1.5	10
99	Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis. Radiotherapy and Oncology, 2019, 132, 188-196.	0.6	20
100	Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database. Breast Cancer Research and Treatment, 2019, 173, 209-216.	2.5	21
101	An Update to Changing Patterns of Anal Carcinoma in the United States. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 887-897.	1.3	5
102	Tumor subtype and other prognostic factors in breast cancer patients with brain metastases: The updated graded prognostic assessment (Breast-GPA) Journal of Clinical Oncology, 2019, 37, 1079-1079.	1.6	4
103	Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database Journal of Clinical Oncology, 2019, 37, 12-12.	1.6	1
104	Comparative Effectiveness of SBRT. , 2019, , 415-424.		0
105	Contemporary changes in localized and metastatic prostate cancer incidence by geographic area following decreased PSA screening Journal of Clinical Oncology, 2019, 37, 1567-1567.	1.6	0
106	Emergency department visits for prescription and synthetic opioid overdoses among patients with cancer Journal of Clinical Oncology, 2019, 37, 6579-6579.	1.6	0
107	Abandonment trajectories of conventionally fractionated adjuvant radiotherapy in breast cancer care Journal of Clinical Oncology, 2019, 37, 531-531.	1.6	1
108	Cost-effectiveness of adjuvant intravaginal brachytherapy in high-intermediate risk endometrial carcinoma. Brachytherapy, 2018, 17, 399-406.	0.5	5

#	Article	IF	Citations
109	Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer. Annals of Oncology, 2018, 29, 386-391.	1.2	17
110	Impact of Widespread Cervical Cancer Screening. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 289-294.	1.3	60
111	Association Between Radiation Dose and Outcomes With Postoperative Radiotherapy for N0-N1 Non–Small Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 152-158.	1.3	6
112	Medicare Cancer Screening in the Context of Clinical Guidelines. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 339-347.	1.3	3
113	Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance. Cancer, 2018, 124, 752-759.	4.1	23
114	Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study. Breast Cancer Research and Treatment, 2018, 167, 479-483.	2.5	27
115	Cost-Effectiveness of Thoracic Radiation Therapy for Extensive-Stage Small Cell Lung Cancer Using Evidence From the Chest Radiotherapy Extensive-Stage Small Cell Lung Cancer Trial (CREST). International Journal of Radiation Oncology Biology Physics, 2018, 100, 97-106.	0.8	2
116	Travel distance and stereotactic body radiotherapy for localized prostate cancer. Cancer, 2018, 124, 1141-1149.	4.1	21
117	Angiotensin receptor blockade: a novel approach for symptomatic radiation necrosis after stereotactic radiosurgery. Journal of Neuro-Oncology, 2018, 136, 289-298.	2.9	4
118	Radiation dose and cardiac risk in breast cancer treatment: An analysis of modern radiation therapy including community settings. Practical Radiation Oncology, 2018, 8, e79-e86.	2.1	30
119	Use of Alternative Medicine for Cancer and Its Impact on Survival. Journal of the National Cancer Institute, 2018, 110, 121-124.	6.3	198
120	Development and Validation of a Multiparameterized Artificial Neural Network for Prostate Cancer Risk Prediction and Stratification. JCO Clinical Cancer Informatics, 2018, 2, 1-10.	2.1	24
121	The Death Spiral of Cancer and Financial Hardship. JNCI Cancer Spectrum, 2018, 2, pky013.	2.9	0
122	Surgeon peer network characteristics and adoption of new imaging techniques in breast cancer: A study of perioperative MRI. Cancer Medicine, 2018, 7, 5901-5909.	2.8	13
123	Pretreatment Identification of Head and Neck Cancer Nodal Metastasis and Extranodal Extension Using Deep Learning Neural Networks. Scientific Reports, 2018, 8, 14036.	3.3	139
124	Physician attitudes about genetic testing for localized prostate cancer: A national survey of radiation oncologists and urologists. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 501.e15-501.e21.	1.6	7
125	Artificial Intelligence in Radiation Oncology Imaging. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1159-1161.	0.8	19
126	The Future of Artificial Intelligence in Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2018, 102, 247-248.	0.8	13

#	Article	IF	CITATIONS
127	Responses to the 2017 "1 Million Gray Question†ASTRO Membership's Opinions on the Most Important Research Question Facing Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2018, 102, 249-250.	0.8	1
128	Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer. Current Oncology Reports, 2018, 20, 66.	4.0	7
129	Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2018, 101, 845-853.	0.8	22
130	Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool. Neuro-Oncology, 2018, 20, 1652-1660.	1.2	47
131	CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 2018, 8, 95.	2.8	36
132	Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers. JAMA Oncology, 2018, 4, 1375.	7.1	215
133	Artificial intelligence in radiation oncology: A specialty-wide disruptive transformation?. Radiotherapy and Oncology, 2018, 129, 421-426.	0.6	175
134	Impact of Health Insurance Status on Prostate Cancer Treatment Modality Selection in the United States. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1062-1068.	1.3	4
135	Mibefradil dihydrochoride with hypofractionated radiation for recurrent glioblastoma: A phase I dose expansion trial Journal of Clinical Oncology, 2018, 36, e14046-e14046.	1.6	7
136	National trends in the management of patients with positive surgical margins at the time of radical prostatectomy Journal of Clinical Oncology, 2018, 36, 111-111.	1.6	2
137	Long-term Quality of Life in Survivors of Brain Metastases: A Roller Coaster of Perspective. Cureus, 2018, 10, e2358.	0.5	1
138	Association between metastatic free interval and recurrent metastatic breast cancer survival: Findings from the Surveillance, Epidemiology and End Results database Journal of Clinical Oncology, 2018, 36, e13069-e13069.	1.6	0
139	Adjuvant chemotherapy and overall survival in adult medulloblastoma. Neuro-Oncology, 2017, 19, now150.	1.2	38
140	Differences in Funding Sources of Phase III Oncology Clinical Trials by Treatment Modality and Cancer Type. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 312-317.	1.3	9
141	Stage I Lung SBRT Clinical Practice Patterns. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 358-361.	1.3	47
142	Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer. Journal of the National Cancer Institute, 2017, 109, djw281.	6.3	5
143	Management of Brain Metastases in Tyrosine Kinase Inhibitor–NaĀ ve Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. Journal of Clinical Oncology, 2017, 35, 1070-1077.	1.6	372
144	The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1069-1077.	0.8	58

#	Article	IF	CITATIONS
145	Attitudes of radiation oncologists toward palliative and supportive care in the United States: Report on national membership survey by the American Society for Radiation Oncology (ASTRO). Practical Radiation Oncology, 2017, 7, 113-119.	2.1	36
146	National treatment trends among older patients with T1-localized renal cell carcinoma11Dr. Simon P. Kim is supported by a career development award from the Conquer Cancer Foundation from the American Society of Clinical Oncology Urologic Oncology: Seminars and Original Investigations, 2017, 35, 113.e15-113.e21.	1.6	24
147	Radiation-Specific Clinical Data Should Be Included in Existing Large-Scale Genomic Datasets. International Journal of Radiation Oncology Biology Physics, 2017, 98, 8-10.	0.8	4
148	Comparing available criteria for measuring brain metastasis response to immunotherapy. Journal of Neuro-Oncology, 2017, 132, 479-485.	2.9	39
149	Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). International Journal of Radiation Oncology Biology Physics, 2017, 99, 812-816.	0.8	163
150	Patterns of care and outcomes for use of concurrent chemoradiotherapy over radiotherapy alone for anaplastic gliomas. Radiotherapy and Oncology, 2017, 125, 258-265.	0.6	3
151	Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiotherapy and Oncology, 2017, 125, 80-88.	0.6	58
152	The Impact of Social Contagion on Physician Adoption of Advanced Imaging Tests in Breast Cancer. Journal of the National Cancer Institute, 2017, 109, .	6.3	40
153	Increased Number of Beam Angles Is Associated With Higher Cardiac Dose in Adjuvant Fixed Gantry Intensity Modulated Radiation Therapy of Left-Sided Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1137-1145.	0.8	8
154	Changes in quality of life after radiation therapy for localized prostate cancer after dissemination of intensity modulated radiation therapy. Journal of Radiation Oncology, 2017, 6, 295-300.	0.7	O
155	Radiosurgery for Brain Metastases: Changing Practice Patterns and Disparities in the United States. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1494-1502.	4.9	57
156	Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer. European Urology, 2017, 72, 738-744.	1.9	33
157	Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Populationâ€Based Study. Prostate, 2017, 77, 437-445.	2.3	24
158	Emerging Technologies and Techniques in Radiation Therapy. Seminars in Radiation Oncology, 2017, 27, 34-42.	2.2	10
159	Association between access to accelerated partial breast irradiation and use of adjuvant radiotherapy. Cancer, 2017, 123, 502-511.	4.1	3
160	Reply to A. Chalmers et al. Journal of Clinical Oncology, 2017, 35, 2340-2341.	1.6	0
161	Treatment Burden of Medicare Beneficiaries With Stage I Non–Small-Cell Lung Cancer. Journal of Oncology Practice, 2017, 13, e98-e107.	2.5	26
162	Hypofractionated Radiotherapy for Prostate Cancer: Further Evidence to Tip the Scales. Journal of Clinical Oncology, 2017, 35, 1867-1869.	1.6	11

#	Article	IF	CITATIONS
163	CDKN2A copy number loss in HPV- and HPV+ head and neck cancer to indicate poor prognosis: An integrated genomic and clinical TCGA analysis Journal of Clinical Oncology, 2017, 35, 6060-6060.	1.6	1
164	Use of alternative medicine for cancer and its impact on survival Journal of Clinical Oncology, 2017, 35, e18175-e18175.	1.6	4
165	Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study. PLoS ONE, 2017, 12, e0184747.	2.5	9
166	Trends and clinico-sociodemographic determinants of stereotactic body radiotherapy use for localized prostate cancer: A National Cancer Database study Journal of Clinical Oncology, 2017, 35, e545-e545.	1.6	0
167	Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States Journal of Clinical Oncology, 2017, 35, 18-18.	1.6	0
168	Outcomes for men under 65 with high-risk prostate cancer with Medicaid versus private insurance Journal of Clinical Oncology, 2017, 35, 198-198.	1.6	0
169	Intensity Modulated Radiotherapy and Image Guidance. , 2016, , 413-426.		1
170	Academic and Resident Radiation Oncologists' Attitudes and Intentions Regarding Radiation Therapy near the End of Life. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 85-89.	1.3	7
171	Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer, 2016, 122, 3051-3058.	4.1	182
172	Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 568-574.	1.3	15
173	Disparities in Treatment of Patients With High-risk Prostate Cancer: Results From a Population-based Cohort. Urology, 2016, 95, 88-94.	1.0	29
174	Cost-effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for up to 10 brain metastases. Journal of Neurosurgery, 2016, 125, 18-25.	1.6	28
175	Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. Radiotherapy and Oncology, 2016, 121, 294-298.	0.6	22
176	The impact of cobalt-60 source age on biologically effective dose in high-dose functional Gamma Knife radiosurgery. Journal of Neurosurgery, 2016, 125, 154-159.	1.6	13
177	Who benefits from chemoradiation in stage Ill–IVA endometrial cancer? An analysis of the National Cancer Data Base. Gynecologic Oncology, 2016, 142, 54-61.	1.4	29
178	Association Between Geographic Access to Cancer Care and Receipt of Radiation Therapy forÂRectal Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 94, 719-728.	0.8	78
179	Cost-Effectiveness of Surgery, Stereotactic Body Radiation Therapy, and Systemic Therapy for Pulmonary Oligometastases. International Journal of Radiation Oncology Biology Physics, 2016, 95, 663-672.	0.8	29
180	Incorporating Androgen Deprivation With Dose-Escalated External-Beam Radiotherapy for Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 1718-1722.	1.6	1

#	Article	IF	Citations
181	Lobectomy versus stereotactic body radiotherapy in healthy patients with stage I lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 44-54.e9.	0.8	105
182	Examination of Industry Payments to Radiation Oncologists in 2014 Using the Centers for Medicare and Medicaid Services Open Payments Database. International Journal of Radiation Oncology Biology Physics, 2016, 94, 19-26.	0.8	16
183	The Association Between Evaluation at Academic Centers and the Likelihood of Expectant Management in Low-risk Prostate Cancer. Urology, 2016, 96, 128-135.	1.0	14
184	Author Reply. Urology, 2016, 96, 134-135.	1.0	0
185	The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 96, 1011-1020.	0.8	28
186	Reply to timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer, 2016, 122, 3577-3578.	4.1	1
187	Reply to J. Du et al. Journal of Clinical Oncology, 2016, 34, 4451-4452.	1.6	O
188	National sociodemographic disparities in the treatment of highâ€risk prostate cancer: Do academic cancer centers perform better than community cancer centers? Cancer, 2016, 122, 3371-3377.	4.1	27
189	Economic Burden Associated with Hospitalization for Radiation Cystitis: Results from a Statewide Inpatient Database. Urology Practice, 2016, 3, 437-442.	0.5	7
190	Concurrent chemoradiotherapy versus radiotherapy alone for "biopsyâ€onlyâ€oglioblastoma multiforme. Cancer, 2016, 122, 2364-2370.	4.1	24
191	Association between Time since Cancer Diagnosis and Health-Related Quality of Life: A Population-Level Analysis. Value in Health, 2016, 19, 631-638.	0.3	30
192	Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncology, The, 2016, 17, 976-983.	10.7	846
193	Radiation Oncology Practice: Adjusting to a New Reimbursement Model. Journal of Oncology Practice, 2016, 12, e576-e583.	2.5	27
194	National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. Cancer, 2016, 122, 1505-1512.	4.1	27
195	Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor–Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2016, 95, 673-679.	0.8	102
196	US radiation oncology practice patterns for posttreatment survivor care. Practical Radiation Oncology, 2016, 6, 50-56.	2.1	16
197	Ceritinib enables stereotactic radiosurgery to a previously untreatable symptomatic brain metastasis in a patient with ALK rearranged non-small cell lung cancer. Cancer Treatment Communications, 2016, 6, 17-19.	0.4	2
198	Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?. Journal of Neurosurgery, 2016, 125, 17-23.	1.6	192

#	Article	IF	CITATIONS
199	Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?. BJU International, 2016, 118, 95-101.	2.5	45
200	Changing practice patterns of Gamma Knife versus linear accelerator-based stereotactic radiosurgery for brain metastases in the US. Journal of Neurosurgery, 2016, 124, 1018-1024.	1.6	61
201	Extended Survival and Prognostic Factors for Patients With <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer and Brain Metastasis. Journal of Clinical Oncology, 2016, 34, 123-129.	1.6	284
202	Digital health application for real-time patient-reported outcomes during prostate radiotherapy Journal of Clinical Oncology, 2016, 34, 157-157.	1.6	3
203	Sequence Assembly of Yarrowia lipolytica Strain W29/CLIB89 Shows Transposable Element Diversity. PLoS ONE, 2016, 11, e0162363.	2.5	68
204	Health State Utilities for Patients with Brain Metastases. Cureus, 2016, 8, e667.	0.5	6
205	Genomic predictors of biochemical failure following radical prostatectomy Journal of Clinical Oncology, 2016, 34, 114-114.	1.6	0
206	The impact of social contagion on physician adoption of breast cancer imaging Journal of Clinical Oncology, 2016, 34, 6534-6534.	1.6	0
207	The benefit of modern cancer therapy for older patients Journal of Clinical Oncology, 2016, 34, e18141-e18141.	1.6	0
208	Attitudes of radiation oncologists toward palliative and supportive care in the United States: Report on National Membership Survey by the American Society for Radiation Oncology (ASTRO) Journal of Clinical Oncology, 2016, 34, 105-105.	1.6	2
209	A Novel Prognostic Index for Ocular Adnexal Lymphoma. Blood, 2016, 128, 3597-3597.	1.4	0
210	Spine Stereotactic Body Radiotherapy Outcomes in Patients with Concurrent Brain Metastases. Cureus, 2016, 8, e679.	0.5	2
211	A contemporary dose selection algorithm for stereotactic radiosurgery in the treatment of brain metastases - An initial report. Journal of Radiosurgery and SBRT, 2016, 4, 43-52.	0.2	7
212	Predicting treatment related imaging changes (TRICs) after radiosurgery for brain metastases using treatment dose and conformality metrics. Journal of Radiosurgery and SBRT, 2016, 4, 53-60.	0.2	1
213	Demonstration of differential radiosensitivity based upon mutation profile in metastatic melanoma treated with stereotactic radiosurgery. Journal of Radiosurgery and SBRT, 2016, 4, 97-106.	0.2	1
214	Patients Selected for Definitive Concurrent Chemoradiation at High-volume Facilities Achieve Improved Survival in Stage III Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 937-943.	1.1	66
215	Gamma Knife radiosurgery for posterior fossa meningiomas: a multicenter study. Journal of Neurosurgery, 2015, 122, 1479-1489.	1.6	79
216	Shared Decision Making and Use of Decision Aids for Localized Prostate Cancer. JAMA Internal Medicine, 2015, 175, 792.	5.1	43

#	Article	IF	CITATIONS
217	In Reply to Wang etÂal. International Journal of Radiation Oncology Biology Physics, 2015, 93, 211-213.	0.8	O
218	In Reply to Rusthoven and Kavanagh. International Journal of Radiation Oncology Biology Physics, 2015, 91, 680-681.	0.8	0
219	Is It the Time for Personalized Imaging Protocols in Cancer Radiation Therapy?. International Journal of Radiation Oncology Biology Physics, 2015, 91, 659-660.	0.8	7
220	Variation in Pelvic Lymph Node Dissection among Patients Undergoing Radical Prostatectomy by Hospital Characteristics and Surgical Approach: Results from the National Cancer Database. Journal of Urology, 2015, 193, 820-825.	0.4	40
221	Assessment of National Practice for Palliative Radiation Therapy for Bone Metastases Suggests Marked Underutilization of Single-Fraction Regimens in the United States. International Journal of Radiation Oncology Biology Physics, 2015, 91, 548-555.	0.8	66
222	Adoption of Intensity Modulated Radiation Therapy For Early-Stage Breast Cancer From 2004 Through 2011. International Journal of Radiation Oncology Biology Physics, 2015, 91, 303-311.	0.8	20
223	Racial disparities in the use of SBRT for treating early-stage lung cancer. Lung Cancer, 2015, 89, 133-138.	2.0	26
224	Stereotactic body radiation therapy: Let's not give up on progress. Practical Radiation Oncology, 2015, 5, 193-196.	2.1	6
225	Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2015, 33, 2727-2734.	1.6	95
226	Gamma Knife radiosurgery for facial nerve schwannomas: a multicenter study. Journal of Neurosurgery, 2015, 123, 387-394.	1.6	31
227	Prophylactic Cranial Irradiation for Patients With Locally Advanced Non–Small-Cell Lung Cancer at High Risk for Brain Metastases. Clinical Lung Cancer, 2015, 16, 292-297.	2.6	29
228	Gamma knife stereotactic radiosurgical thalamotomy for intractable tremor: A systematic review of the literature. Radiotherapy and Oncology, 2015, 114, 296-301.	0.6	51
229	Association between Surgeon and Hospital Characteristics and Lymph Node Counts From Radical Prostatectomy and Pelvic Lymph Node Dissection. Urology, 2015, 85, 890-895.	1.0	11
230	Historical trends of radiotherapy use in prevalent malignancies over 38Âyears in SEER. Journal of Radiation Oncology, 2015, 4, 11-17.	0.7	3
231	Change in radiotherapy treatment volumes with initial alkylating chemotherapy in anaplastic gliomas. Journal of Radiation Oncology, 2015, 4, 163-167.	0.7	0
232	Adjuvant Carboplatin, Paclitaxel, and Vaginal Cuff Brachytherapy for Stage III Endometrial Cancer. International Journal of Gynecological Cancer, 2015, 25, 431-439.	2.5	14
233	Comparative effectiveness of surgery and radiosurgery for stage <scp>I</scp> non–small cell lung cancer. Cancer, 2015, 121, 2341-2349.	4.1	74
234	Older Women With Localized Breast Cancer: Costs And Survival Rates Increased Across Two Time Periods. Health Affairs, 2015, 34, 592-600.	5.2	15

#	Article	IF	CITATIONS
235	Regional-Level Correlations in Inappropriate Imaging Rates for Prostate and Breast Cancers. JAMA Oncology, 2015, 1, 185.	7.1	50
236	Hypofractionated radiation therapy versus conventionally fractionated radiation therapy for early-stage breast cancer: how do we choose?. Future Oncology, 2015, 11, 2105-2107.	2.4	2
237	Defining the High-Risk Population for Mortality After Resection of Early Stage NSCLC. Clinical Lung Cancer, 2015, 16, e183-e187.	2.6	32
238	Role of Chemoradiotherapy in Elderly Patients With Limited-Stage Small-Cell Lung Cancer. Journal of Clinical Oncology, 2015, 33, 4240-4246.	1.6	52
239	Association Between Geographic Access to Cancer Care, Insurance, and Receipt of Chemotherapy: Geographic Distribution of Oncologists and Travel Distance. Journal of Clinical Oncology, 2015, 33, 3177-3185.	1.6	187
240	"The burden upon me― The complexity of healthcare utilization among Medicare patients undergoing curative lung cancer treatment Journal of Clinical Oncology, 2015, 33, 7533-7533.	1.6	1
241	Association between radiation dose and outcomes with postoperative radiotherapy for N0-N1 non-small-cell-lung cancer Journal of Clinical Oncology, 2015, 33, 7538-7538.	1.6	1
242	Changes in prostate cancer presentation for radiation oncology care after USPSTF recommendations, 2007-2013 Journal of Clinical Oncology, 2015, 33, e16070-e16070.	1.6	1
243	Factors associated with high-volume providers of stereotactic radiation therapy for Medicare beneficiaries in 2012 Journal of Clinical Oncology, 2015, 33, e17578-e17578.	1.6	1
244	Association between provider-level factors and lymph node dissection outcomes during radical prostatectomy: A national cancer database analysis Journal of Clinical Oncology, 2015, 33, 89-89.	1.6	0
245	Association between geographic access to cancer care and receipt of chemotherapy: Geographic distribution of oncologists and travel distance Journal of Clinical Oncology, 2015, 33, e17561-e17561.	1.6	0
246	Medicare cancer screening in the context of clinical guidelines: 2000-2012 Journal of Clinical Oncology, 2015, 33, e17579-e17579.	1.6	0
247	Secondary Myeloid Neoplasms in Older Women with Breast Cancer after Radiotherapy: A Population-Based Study. Blood, 2015, 126, 1676-1676.	1.4	0
248	The cost of cancer-related physician services to Medicare. Yale Journal of Biology and Medicine, 2015, 88, 107-14.	0.2	2
249	Equivalent whole brain dose for patients undergoing gamma knife for multiple lesions. Journal of Radiosurgery and SBRT, 2015, 3, 187-191.	0.2	1
250	Response. Journal of the National Cancer Institute, 2014, 106, dju198-dju198.	6.3	0
251	Estimating the magnitude of colorectal cancers prevented during the era of screening: 1976 to 2009. Cancer, 2014, 120, 2893-2901.	4.1	71
252	Revisiting the Sustainable Growth Rate "Hole†Sources of Healthcare Cost Stabilization in 2010-2012. International Journal of Radiation Oncology Biology Physics, 2014, 90, 983-985.	0.8	3

#	Article	IF	Citations
253	Adoption of Hypofractionated Whole-Breast Irradiation for Early-Stage Breast Cancer: AÂNational Cancer Data Base Analysis. International Journal of Radiation Oncology Biology Physics, 2014, 90, 993-1000.	0.8	72
254	Understanding Regional Variation in Medicare Expenditures for Initial Episodes of Prostate Cancer Care. Medical Care, 2014, 52, 680-687.	2.4	18
255	Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer. Medical Care, 2014, 52, 579-585.	2.4	42
256	Examining the Cost-Effectiveness of Radiation Therapy Among Older Women With Favorable-Risk Breast Cancer. Journal of the National Cancer Institute, 2014, 106, dju008.	6.3	33
257	Reply to K. Quan et al, S.P. Collins et al, C.R. King et al, S. Arcangeli et al, D.B. Fuller, and D. Vordermark. Journal of Clinical Oncology, 2014, 32, 3456-3457.	1.6	0
258	For-profit hospital ownership status and use of brachytherapy after breast-conserving surgery. Surgery, 2014, 155, 776-788.	1.9	8
259	Decision Analysis of Stereotactic Radiation Surgery Versus Stereotactic Radiation Surgery and Whole-Brain Radiation Therapy for 1 to 3 Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2014, 89, 563-568.	0.8	11
260	Poorer Prognosis of African-American Patients With Mycosis Fungoides: An Analysis of the SEER Dataset, 1988 to 2008. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 419-423.	0.4	43
261	Significance of histology in determining management of lesions regrowing after radiosurgery. Journal of Neuro-Oncology, 2014, 117, 303-310.	2.9	22
262	Delayed Cerebral Vasculopathy Following Cranial Radiation Therapy for Pediatric Tumors. Pediatric Neurology, 2014, 50, 549-556.	2.1	38
263	The cost implications of prostate cancer screening in the Medicare population. Cancer, 2014, 120, 96-102.	4.1	50
264	Gamma Knife radiosurgery for sellar and parasellar meningiomas: a multicenter study. Journal of Neurosurgery, 2014, 120, 1268-1277.	1.6	83
265	Considerations for Observational Research Using Large Data Sets in Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2014, 90, 11-24.	0.8	70
266	Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy for Prostate Cancer: Comparison of Toxicity. Journal of Clinical Oncology, 2014, 32, 1195-1201.	1.6	133
267	Stereotactic radiosurgery of petroclival meningiomas: a multicenter study. Journal of Neuro-Oncology, 2014, 119, 169-176.	2.9	50
268	Comparative Effectiveness Research in Radiation Oncology: Stereotactic Radiosurgery, Hypofractionation, and Brachytherapy. Seminars in Radiation Oncology, 2014, 24, 35-42.	2.2	12
269	The global cancer divide: Relationships between national healthcare resources and cancer outcomes in high-income vs. middle- and low-income countries. Journal of Epidemiology and Global Health, 2014, 4, 115.	2.9	28
270	Treating Locally Advanced Disease: An Analysis of Very Large, Hilar Lymph Node Positive Non-Small Cell Lung Cancer Using the National Cancer Data Base. Annals of Thoracic Surgery, 2014, 97, 1149-1155.	1.3	9

#	Article	IF	Citations
271	Perceptions of Radiation Oncologists and Urologists onÂSources and Type of Evidence to Inform Prostate Cancer Treatment Decisions. International Journal of Radiation Oncology Biology Physics, 2014, 89, 277-283.	0.8	3
272	Estimating the impact of screening on three decades of cervical cancer incidence Journal of Clinical Oncology, 2014, 32, 1518-1518.	1.6	1
273	Diffusion of stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer (NSCLC) in the Medicare population, 2007-2009 Journal of Clinical Oncology, 2014, 32, 7575-7575.	1.6	2
274	Perceptions of radiation oncologists and urologists on the type of evidence that informs and changes the clinical practice of prostate cancer Journal of Clinical Oncology, 2014, 32, 167-167.	1.6	0
275	Perceptions of radiation oncologists and urologists about new technology for the treatment of prostate cancer Journal of Clinical Oncology, 2014, 32, e16085-e16085.	1.6	0
276	In regards to decision making for reirradiation of a recurrent intramedullary spinal cord metastasis. Journal of Radiosurgery and SBRT, 2014, 3, 165-168.	0.2	0
277	The influence of regional health system characteristics on the surgical management and receipt of post operative radiation therapy for glioblastoma multiforme. Journal of Neuro-Oncology, 2013, 112, 393-401.	2.9	28
278	A new approach to understanding racial disparities in prostate cancer treatment. Journal of Geriatric Oncology, 2013, 4, 1-8.	1.0	37
279	Historical Trends in the Use of Radiation Therapy for Pediatric Cancers: 1973-2008. International Journal of Radiation Oncology Biology Physics, 2013, 85, e151-e155.	0.8	97
280	Variation in Treatment Recommendations of Adjuvant Radiation Therapy for High-risk Prostate Cancer by Physician Specialty. Urology, 2013, 82, 807-813.	1.0	31
281	The Adoption of New Adjuvant Radiation Therapy Modalities Among Medicare Beneficiaries With Breast Cancer: Clinical Correlates and Cost Implications. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1186-1192.	0.8	40
282	National Residency Matching Program Results for Radiation Oncology: 2012 Update. International Journal of Radiation Oncology Biology Physics, 2013, 86, 402-404.	0.8	6
283	Impact of preoperative radiation on survival of patients with T3N0 >7-cm non–small cell lung cancers treated with anatomic resection using the Surveillance, Epidemiology, and End Results database. Journal of Surgical Research, 2013, 184, 10-18.	1.6	7
284	The relation between age and androgen deprivation therapy use among men in the Medicare population receiving radiation therapy for prostate cancer. Journal of Geriatric Oncology, 2013, 4, 9-18.	1.0	0
285	Interpreting cost-utility analysis of prostate cancer treatment. Nature Reviews Urology, 2013, 10, 129-131.	3.8	1
286	Role of stereotactic radiosurgery in patients with more than four brain metastases. CNS Oncology, 2013, 2, 181-193.	3.0	21
287	Proton Versus Intensity-Modulated Radiotherapy for Prostate Cancer: Patterns of Care and Early Toxicity. Journal of the National Cancer Institute, 2013, 105, 25-32.	6.3	151
288	Reply to L.W. Cuttino et al. Journal of Clinical Oncology, 2013, 31, 2227-2229.	1.6	2

#	Article	IF	Citations
289	A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2013, 19, 5523-5532.	7.0	82
290	Response. Journal of the National Cancer Institute, 2013, 105, 748-749.	6.3	0
291	Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 486-490.	1.3	30
292	Determinants of Enrollment in Cancer Clinical Trials: The Relationship Between the Current State of Knowledge, Societal Disease Burden, and Randomized Clinical Trial Enrollment. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 928-936.	4.9	1
293	Variation in Receipt of Radiation Therapy After Breast-conserving Surgery. Medical Care, 2013, 51, 330-338.	2.4	25
294	For-profit hospital ownership status and use of brachytherapy after breast-conserving surgery Journal of Clinical Oncology, 2013, 31, 6511-6511.	1.6	1
295	The cost implications of prostate cancer screening in the Medicare population Journal of Clinical Oncology, 2013, 31, 6549-6549.	1.6	0
296	The Prognostic Importance of Midline Involvement in Oral Tongue Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 468-473.	1.3	7
297	Status Quoâ€"Standard-of-Care Medical and Radiation Therapy for Glioblastoma. Cancer Journal (Sudbury, Mass), 2012, 18, 12-19.	2.0	60
298	Patterns of Use and Short-Term Complications of Breast Brachytherapy in the National Medicare Population From 2008–2009. Journal of Clinical Oncology, 2012, 30, 4302-4307.	1.6	67
299	Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. Journal of Neurosurgery, 2012, 117, 227-233.	1.6	296
300	The impact of county-level radiation oncologist density on prostate cancer mortality in the United States. Prostate Cancer and Prostatic Diseases, 2012, 15, 391-396.	3.9	25
301	Cross Talk Between Estradiol and mTOR Kinase in the Regulation of Ovarian Granulosa Proliferation. Reproductive Sciences, 2012, 19, 143-151.	2.5	16
302	Assessing the Impact of a Cooperative Group Trial on Breast Cancer Care in the Medicare Population. Journal of Clinical Oncology, 2012, 30, 1601-1607.	1.6	112
303	Appropriate And Inappropriate Imaging Rates For Prostate Cancer Go Hand In Hand By Region, As If Set By Thermostat. Health Affairs, 2012, 31, 730-740.	5.2	35
304	The Relationship Between Clinical Benefit and Receipt of Curative Therapy for Prostate Cancer. Archives of Internal Medicine, 2012, 172, 362.	3.8	10
305	Geographic Analysis of the Radiation Oncology Workforce. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1723-1729.	0.8	49
306	Testicular Doses in Image-Guided Radiotherapy of Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, e39-e47.	0.8	27

#	Article	IF	CITATIONS
307	Immortal Time Bias: A Frequently Unrecognized Threat to Validity in the Evaluation of Postoperative Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1365-1373.	0.8	156
308	Patterns of Care and Outcomes Associated With Intensity-Modulated Radiation Therapy Versus Conventional Radiation Therapy for Older Patients WithAHead-and-Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, e101-e107.	0.8	21
309	In regard to "Indications for Pelvic Nodal Treatment in Prostate Cancer Should Change. Validation of the Roach Formula in a Large Extended Nodal Dissection Series.―(Int J Radiat Oncol Biol Phys) Tj ETQq1 1 0.784	3 <b>1048</b> rgBT	Overlock 10
310	National Residency Matching Program (NRMP) Results for Radiation Oncology: 2011 Update. International Journal of Radiation Oncology Biology Physics, 2012, 83, 771-772.	0.8	10
311	How Radiation Oncologists Would Disclose Errors: Results of a Survey of Radiation Oncologists and Trainees. International Journal of Radiation Oncology Biology Physics, 2012, 84, e131-e137.	0.8	7
312	The Population Level Prevalence and Correlates of Appropriate and Inappropriate Imaging to Stage Incident Prostate Cancer in the Medicare Population. Journal of Urology, 2012, 187, 97-102.	0.4	42
313	Radiosurgical Dose Selection for Brain Metastasis. Progress in Neurological Surgery, 2012, 25, 139-147.	1.3	10
314	Age, Race, Sex, Stage, and Incidence of Cutaneous Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 291-296.	0.4	119
315	Overview of the Surveillance, Epidemiology, and End Results Database: Evolution, Data Variables, and Quality Assurance. Current Problems in Cancer, 2012, 36, 183-190.	2.0	112
316	Using the Surveillance, Epidemiology, and End Results Database to Investigate Rare Cancers, Second Malignancies, and Trends in Epidemiology, Treatment, and Outcomes. Current Problems in Cancer, 2012, 36, 191-199.	2.0	12
317	Prediction Models, Nomograms, and Staging Validation with the Surveillance, Epidemiology, and End Results Database. Current Problems in Cancer, 2012, 36, 200-207.	2.0	1
318	Comparative Effectiveness Research and the Surveillance, Epidemiology, and End Results Database. Current Problems in Cancer, 2012, 36, 208-215.	2.0	1
319	Limitations and Biases of the Surveillance, Epidemiology, and End Results Database. Current Problems in Cancer, 2012, 36, 216-224.	2.0	98
320	Role of Neurosurgery and Radiation Therapy in the Management of Brain Tumors. Hematology/Oncology Clinics of North America, 2012, 26, 757-777.	2.2	5
321	Complications of Brain Tumors and Their Treatment. Hematology/Oncology Clinics of North America, 2012, 26, 779-796.	2.2	29
322	Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a Surveillance, Epidemiology, and End Results analysis. Cancer, 2012, 118, 4212-4219.	4.1	144
323	The influence of regional radiation oncologist and urologist capacities on treatment choice for prostate cancer management Journal of Clinical Oncology, 2012, 30, 108-108.	1.6	0
324	An assessment of the collective efforts of clinical trials to provide evidence-based practice guidelines in cancer care Journal of Clinical Oncology, 2012, 30, 6019-6019.	1.6	0

#	Article	IF	Citations
325	Proton radiotherapy for prostate cancer in the Medicare population: Patterns of care and comparison of early toxicity with IMRT Journal of Clinical Oncology, 2012, 30, 4651-4651.	1.6	0
326	Short-term complications and use of breast brachytherapy in the national Medicare population in 2008-2009 Journal of Clinical Oncology, 2012, 30, 1030-1030.	1.6	12
327	The relations between age and androgen deprivation therapy use among men receiving radiation therapy for prostate cancer in the Medicare population Journal of Clinical Oncology, 2012, 30, e15150-e15150.	1.6	0
328	Hypofractionated radiation therapy for prostate cancer: risks and potential benefits in a fiscally conservative health care system. Oncology, 2012, 26, 512-8.	0.5	14
329	Adjuvant radiotherapy after radical prostatectomy: Evidence and analysis. Cancer Treatment Reviews, 2011, 37, 89-96.	7.7	14
330	Melanoma Brain Metastases: Is It Time to Reassess the Bias?. Current Problems in Cancer, 2011, 35, 200-210.	2.0	33
331	A significant decrease in rectal volume and diameter during prostate IMRT. Radiotherapy and Oncology, 2011, 98, 187-191.	0.6	21
332	Population Based Cancer Registry Analysis of Primary Tracheal Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 32-37.	1.3	154
333	The Association Between Diffusion of the Surgical Robot and Radical Prostatectomy Rates. Medical Care, 2011, 49, 333-339.	2.4	82
334	Determinants and Patterns of Survival in Adenoid Cystic Carcinoma of the Head and Neck, Including an Analysis of Adjuvant Radiation Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 76-81.	1.3	151
335	Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood, 2011, 117, 412-418.	1.4	217
336	Radiation Therapy Definitions and Reporting Guidelines for Thymic Malignancies. Journal of Thoracic Oncology, 2011, 6, S1743-S1748.	1.1	78
337	The Impact of Pretreatment Prostate Volume on Severe Acute Genitourinary Toxicity in Prostate Cancer Patients Treated With Intensity-Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2011, 79, 379-384.	0.8	31
338	A New Formula for Prostate Cancer Lymph Node Risk. International Journal of Radiation Oncology Biology Physics, 2011, 80, 69-75.	0.8	40
339	Hippocampal-Sparing Whole-Brain Radiotherapy: A "How-To―Technique Using Helical Tomotherapy and Linear Accelerator-Based Intensity-Modulated Radiotherapy: In Regard to Gondi V, et al. (Int J Radiat) Tj ETQq1 379, 957-958.	0.784314	rgBT /Overlo
340	In Response to Dr. Hayes and Colleagues. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1598-1599.	0.8	0
341	National Residency Matching Program (NRMP) Results for Radiation Oncology: 2010 Update. International Journal of Radiation Oncology Biology Physics, 2011, 80, 4-5.	0.8	5
342	In Reply to Drs. Oymak and Onal. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1603-1604.	0.8	0

#	Article	IF	Citations
343	Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: an update. Expert Review of Anticancer Therapy, 2011, 11, 1731-1738.	2.4	16
344	mTOR Controls Ovarian Follicle Growth by Regulating Granulosa Cell Proliferation. PLoS ONE, 2011, 6, e21415.	2.5	69
345	Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 215-219.	1.1	167
346	Analysis of pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort. Cancer, 2010, 116, 5757-5766.	4.1	32
347	A Prognostic Index for Predicting Lymph Node Metastasis in Minor Salivary Gland Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 76, 169-175.	0.8	55
348	Surveillance, Epidemiology, and End Results (SEER) Database Analysis of Microcystic Adnexal Carcinoma (Sclerosing Sweat Duct Carcinoma) of the Skin. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 125-127.	1.3	77
349	Long-term response to fractionated radiotherapy of presumed optic nerve sheath meningioma. British Journal of Ophthalmology, 2010, 94, 559-563.	3.9	52
350	Validation of the Partin Nomogram for Prostate Cancer in a National Sample. Journal of Urology, 2010, 183, 105-111.	0.4	47
351	A retrospective review of 1349 cases of sebaceous carcinoma. Cancer, 2009, 115, 158-165.	4.1	288
352	Whole Pelvic Radiotherapy Versus Prostate Only Radiotherapy in the Management of Locally Advanced or Aggressive Prostate Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1344-1349.	0.8	83
353	Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma. Radiotherapy and Oncology, 2009, 93, 185-191.	0.6	58
354	Patient Perspectives Regarding the Value of Total Skin Electron Beam Therapy for Cutaneous T-Cell Lymphoma/Mycosis Fungoides. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 142-144.	1.3	15
355	NCI SEER public-use data: applications and limitations in oncology research. Oncology, 2009, 23, 288-95.	0.5	129
356	The Role of Postoperative Radiation Therapy (PORT) in the Treatment of Extrahepatic Bile Duct Cancer: A Surveillance, Epidemiology, and End Results (SEER) Population-Based Investigation. Journal of Gastrointestinal Cancer, 2008, 39, 11-21.	1.3	4
357	Postmastectomy radiation therapy for lymph nodeâ€negative, locally advanced breast cancer after modified radical mastectomy. Cancer, 2008, 113, 38-47.	4.1	31
358	Treatment of Primary Cutaneous CD30+ Anaplastic Large-Cell Lymphoma With Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1542-1545.	0.8	52
359	Analysis of Primary CD30+ Cutaneous Lymphoproliferative Disease and Survival From the Surveillance, Epidemiology, and End Results Database. Journal of Clinical Oncology, 2008, 26, 1483-1488.	1.6	41
360	Impact of Immediate Postoperative Death on the Estimation of a Survival Benefit From Postoperative Radiation Therapy for Cancer of the Gallbladder. Journal of Clinical Oncology, 2008, 26, 4523-4523.	1.6	4

#	Article	IF	CITATIONS
361	Superior Vena Cava Syndrome—A Proposed Classification System and Algorithm for Management. Journal of Thoracic Oncology, 2008, 3, 811-814.	1.1	133
362	A Dosimetric Evaluation of Conventional Helmet Field Irradiation Versus Two-Field Intensity-Modulated Radiotherapy Technique. International Journal of Radiation Oncology Biology Physics, 2007, 68, 621-631.	0.8	15
363	National Residency Matching Program (NRMP) Results forÂRadiationÂOncology: 2007 Update. International Journal of Radiation Oncology Biology Physics, 2007, 69, 326-327.	0.8	8
364	Phosphorylated FADD induces NF-κB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 12507-12512.	7.1	122